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Purpose: The aim of this study was to review institutional outcomes for advanced thyroid cancers
treated with fast neutron radiation therapy (FNRT) and photon radiation therapy (RT).
Methods and materials: In all, 62 consecutive patients were analyzed. Fifty-nine had stage IV
disease. Twenty-three were treated with FNRT and 39 with photon RT. Median follow-up was 14
months. The primary endpoint was overall survival (OS).
Results: There was no signiﬁcant difference in median OS between FNRT and photon RT (26 vs
16 months; P Z .49). Patients with well-differentiated histologies had superior median OS with
photon RT (17 vs 69 months; P Z .04). There was a nonsigniﬁcant trend toward improved OS
with FNRT for medullary and anaplastic histologies.
Conclusions: Outcomes in this study are in line with historical results. There is an apparent
detriment in OS with FNRT for well-differentiated histologies and a trend toward improved OS
with medullary and anaplastic histologies that warrants further investigation.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Thyroid malignancies are relatively rare. In the United
States in 2015, it is estimated that there will be 62,450Results from this work were presented at the 57th Annual Scientiﬁc
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article under the CC BY-NC-ND license (http://creativecommons.org/licenses/new cases and 1950 deaths.1 There has, however, been a
recent increase in the incidence of thyroid cancer, mostly
attributed to improvements in diagnostic techniques that
can better identify early-stage disease.2 Although
accounting for only 0.3% of all cancer deaths, thyroid
cancer is the most common endocrine malignancy and
accounts for 64% of deaths from this type of disease.3
Thyroid cancers are generally divided into 4 broad
categories based on histology: (1) well-differentiated
malignancies (papillary thyroid cancer [PTC], follicular
thyroid cancer [FTC], mixed papillary and follicular his-
tology and Hürthle cell); (2) medullary thyroid cancerof the American Society for Radiation Oncology. This is an open access
by-nc-nd/4.0/).
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cancers that include lymphoma and sarcoma.4 These
various cancers generally arise from 2 predominant
parenchymal cells within the thyroid, the follicular cells
that concentrate iodine and develop into well-
differentiated and ATC and parafollicular or C cells that
produce calcitonin and give rise to MTC. The majority of
thyroid cancers are well-differentiated, accounting for
approximately 90% of all diagnoses. These include 75%
PTC, 10% FTC, and 2% to 5% Hürthle cell. In addition,
MTC accounts for 5% to 9% of diagnoses (6% sporadic
and 3% familial) and ATC accounts for 1% to 2%.
Finally, the remaining 2% of thyroid cancers are
comprised of sarcomas, lymphomas and other rare
entities.5 Exposure to ionizing radiation is the only known
extrinsic risk factor associated with thyroid carcinoma,
most often resulting in PTC.6
Treatment strategies for the various thyroid malig-
nancies are based upon histology, extent of tumor at
diagnosis, and age. Separate stage groupings are recom-
mended for well-differentiated, MTC, and ATC by the
American Joint Committee on Cancer (AJCC).7 Age is
considered a prognostic factor in the case of PTC and
FTC, with all patients younger than 45 years being either
stage I or II based on the presence or absence of distant
metastases. This staging scheme reﬂects the excellent
outcomes associated with this population of patients,
which is in stark contrast to those with ATC, who are all
considered to have stage IV disease and generally have
poor outcomes.8,9
The mainstay of therapy for thyroid carcinoma is
surgical resection, typically with near-total or total thy-
roidectomy and neck dissection (including at least the
central compartment).10 In the case of well-differentiated
thyroid cancers, which typically concentrate iodine,
consideration is also made of subsequent radioiodine
(RAI) remnant ablation. The use of adjuvant external
beam radiation (EBRT) is controversial in this group (and
for MTC); however, it is often indicated for patients older
than 45 years of age with a high likelihood of microscopic
residual disease or gross residual/unresectable dis-
ease.10,11 The role for EBRT for ATC is well-established
as a critical component of trimodality therapy for patients
with limited disease and in the palliation of gross disease
in unresectable cases.12 In spite of this, outcomes are still
poor, and ATC is considered relatively radioresistant.13
The majority of thyroid cancers treated with EBRT are
therefore locally advanced, node-positive, unresectable,
and/or ATC. Local control and survival are suboptimal
for patients with stage IV disease treated with conven-
tional photon EBRT, with approximately 15% to 25%
local recurrences in well-differentiated disease8,14 and
30% in MTC.15 Also, ATC typically has a median overall
survival (OS) of only 4 to 5 months.16,17 Beginning in the
1980s, there was a great deal of interest in examining the
potential for improved outcomes with fast neutron RT(FNRT) versus photon radiation therapy (RT) in a wide
variety of tumors.18 This was driven by preclinical data
showing improved cell killing for tumor cells that were
hypoxic or in radioresistant phases of the cell cycle and
preferential killing of repair-proﬁcient tumor cells.19
Several retrospective studies and a single prospective
study demonstrated an advantage in local control with the
use of high linear energy transfer neutron RT compared
with photon RT in the treatment of a variety of salivary
gland neoplasms, sarcomas of the bone and soft tissue,
and metastatic renal cell carcinoma.20e27
Because of the encouraging data with other histologies
and radiobiological rationale, we began treating patients
with FNRT for advanced thyroid cancer in the mid-1980s,
with the hypothesis that this modality could potentially
improve survival in a patient cohort that typically did
poorly with photon RT, particularly in the case of the
“radioresistant” ATC, in which shorter treatment times
might mitigate rapid tumor cell proliferation. In this study,
we sought to compare the relative efﬁcacy of FNRT and
photon RT in the treatment of advanced thyroid malig-
nancies over a 30-year period. Here we present our
institutional experience, the ﬁrst such retrospective study
to explore the utility of FNRT in advanced thyroid cancer.
Methods and materials
After obtaining institutional review board approval, we
retrospectively reviewed the medical records of 64
patients treated at our institution for primary thyroid
malignancy from 1985 to 2015. Patients receiving palli-
ation for distant metastases (DM) and those with second,
synchronous primaries were excluded. One patient treated
with FNRT had no follow-up or survival data and 1 in the
photon RT group had a parathyroid primary. Both were
excluded, leaving 62 patients for evaluation.
Twenty-three patients were treated with FNRT and 39
with photon RT. Patients were determined to be alive or
deceased (date of death determined) from a review of
medical charts, telephone interviews with patients, fam-
ilies, referring physicians, review of the social security
death index, and/or review of local obituaries. Tumors
arising in the thyroid gland were staged according to
staging criteria as published by the AJCC (7th ed.) in
2010. This staging system is primarily based on age at
presentation, the size and histology of the primary lesion,
and the presence or absence of lymph node involvement
and metastasis.7
Patient characteristics
All patients included in the study had evidence of 1 or
more of the following: gross residual disease at the time
of treatment, positive lymph nodes as determined by
resection, lymph nodes with evidence of extracapsular
Table 2 Treatment characteristics
Neutron Photon
No. (%) No. (%)
Dose (NcGy/cGy)
Median 1920 6380
Range 1380-2040 500-7200
Fractions
Median 16 33
Range 12-17 2-60
Dose/fraction
Median 120 212
Range 115-123 120-300
Twice-daily treatment
Yes 0 0 8 21
No 23 100 28 72
Unknown 0 0 3 8
Concurrent Chemotherapy
Yes 2 9 14 36
No 21 91 25 64
NcGy, neutron centigray.
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positive margins, radiographic evidence for residual dis-
ease, or a surgical report documenting the presence of
residual disease. Many patients had multiple factors.
Patient characteristics in the 2 treatment groups were
relatively well-balanced (Table 1). There were approxi-
mately equal numbers of men and women in the 2
groups. The median age at the time of treatment was 59
years in both groups, with a range from 22 to 88 years in
the FNRT group and 19 to 88 years in the photon RT
group. Documentation was available to stage the primary
tumor in all patients. All 23 patients in the FNRT group
had stage IV disease. Thirty-six of 39 patients in the
photon RT group had stage IV disease, with 2 stage I and
1 stage II. All 3 non-stage IV patients had papillary
histology and were <45 years old. Primary tumor his-
tologies were generally well balanced between the 2
treatment groups, with fewer MTC (8% vs 30%) in the
photon RT group.
We speciﬁcally assessed the presence or absence of
DM disease at presentation in the ATC group because
this has been shown to be prognostic for both disease-
speciﬁc survival and OS.28 In the FNRT group, 1 of 7
patients had DM compared with 6 of 17 in the photon RT
group.Treatment technique
Treatment characteristics are summarized in Table 2.
Treatment modality was selected by the treating physi-
cian, and both FNRT and photon RT were used routinelyTable 1 Patient characteristics
Neutron Photon
No. (%) No. (%)
Sex
Male 11 48 22 56
Female 12 52 17 44
Age, y
Median 59 59
Range 22-88 19-88
American Joint Committee on Cancer stage
I 0 0 2 5
II 0 0 1 3
IV 23 100 36 92
Histology
Papillary 6 26 17 44
Follicular 1 4 0 0
Medullary 7 30 3 8
Anaplastic 7 30 17 44
Other 2 9 2 5
Anaplastic with distant metastases
Yes 1 14 6 35
No 6 86 11 65during the study period. All patients in the FNRT group
were treated using a Scanditronix cyclotron (Scanditronix,
Uppsala, Sweden) with a 50.5-MeV proton-beryllium
reaction used to produce the neutron beam. The depth-
dose characteristics of the resulting beam are similar to
an 8-MV photon beam. The unit has isocentric capabil-
ities with a rotating gantry. Conformal ﬁeld shaping was
accomplished by the use of multileaf collimation. The
median dose delivered to the gross tumor volume was
1920 neutron centigray (NcGy). The median fraction
number was 16 and dose per fraction 120 NcGy. Treat-
ments were delivered daily, 4 days per week. No patients
were treated twice daily and only 2 received concurrent
chemotherapy. FNRT doses were selected based on a
relative biological effectiveness (RBE) of 3.329 for late
effects in normal tissues, representing an equivalent of
6336 cGy of photon RT. Initially, patients were treated
with doses of >2000 NcGy based on contemporary Ra-
diation Therapy Oncology Group protocols. This dose
was ultimately reduced to 1840 NcGy after the publica-
tion of studies revealing high rates of late complications at
the higher doses.30,31
All patients in the photon RT group were treated
using linear accelerators capable of producing 6 MV
photons or greater. Conformal ﬁeld shaping was
accomplished by using either multileaf collimation or
custom Cerrobend blocks. More recently, patients have
been treated with intensity modulated RT with a dose
painted technique. The median dose delivered to the
gross tumor volume was 6380 cGy (range, 500-7200) in
a median of 33 fractions. The median dose per fraction
was 212 cGy. Eight of 39 patients were treated with
twice-daily regimens, and 14 of 39 received concurrent
chemotherapy.
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The primary endpoint of this study was OS. This was
deﬁned from the date of the last fraction of RT. Survival
rates were calculated using the Kaplan-Meier method.
Survival rates were calculated for all patients based on
primary tumor histology and treatment type (FNRT vs
photon RT). For the purposes of our analysis, PTC and
FTC were grouped together as “well-differentiated” his-
tologies. Subset analyses were performed, comparing
FNRT versus photon RT by histology. Log-rank tests
were applied to compare OS between groups and sub-
groups. Uni- and multivariate Cox proportional hazard
models were constructed to test for statistical association
with OS. All statistical calculations were performed using
OriginPro, version 9.1 (OriginLab Corporation, North-
ampton, MA).
Results
All patients
Median follow-up was 14 months for the entire patient
cohort and 29 months for surviving patients. Median
follow-up in the FNRT group was 17 months versus 11
months in the photon RT group. At the time of analysis,
19 of 23 FNRT and 28 of 39 photon RT patients had died
(83% and 72%, respectively). Three FNRT and 8 photon
RT patients were alive (within 6 months of data collec-
tion), with only 1 FNRT (12 months) and 3 photon RT
patients (2, 5, and 34 months) lost to follow-up. There
was a statistically signiﬁcant difference in OS when
comparing histology (Fig 1, log-rank P < .0001), with
median OS of 54, 36, and 4 months for MTC, well
differentiated, and ATC, respectively. The Kaplan-Meier
estimated OS at 1 year was 90%, 78%, and 23%
respectively. There was no difference in OS betweenFigure 1 Survival outcomes based on primary histology.
Kaplan-Meier curves demonstrating OS with 95% conﬁdence
interval. Vertical lines designate censored events. OS, overall
survival.FNRT and photon RT-based treatment when examining
the entire patient cohort, with median OS of 26 and 16
months, respectively (Fig 2, P Z .49). The following
covariates were examined for the entire cohort: age,
gender, histology, radiation type, and presence/absence of
concurrent chemotherapy. By univariate analysis,
increasing age, anaplastic histology, and concurrent
chemotherapy predicted worse OS, with hazard ratios
(HR) of 1.04 (95% CI [conﬁdence interval], 1.02-1.07),
2.19 (95% CI, 1.59-3.12), and 3.25 (95% CI, 1.68-6.27),
respectively. On multivariate analysis, both anaplastic
histology and concurrent chemotherapy remained signif-
icant, with HR of 2.08 (95% CI, 1.41-3.05) and 2.32
(95% CI, 1.19-4.50), respectively.
Subgroup analysis
Given the inherent differences in prognosis and tumor
biology depending on histology, we also performed sub-
group analyses by histology for FNRT versus photon RT.
For well-differentiated histologies (PTC/FTC), there was a
statistically signiﬁcant difference in OS favoring photon RT
(Fig 3), with median OS of 17 months for FNRT and 69
months for photon RT (P Z .04). By Cox proportional
hazard modeling, the HR was 0.34 (95% CI, 0.12-0.97),
favoring photon RT. For patients with MTC, there was a
trend toward an improvement in OS, with a median OS of
211months for FNRTand 54months for photonRT (Fig 4);
however, this was not statistically signiﬁcant (PZ .19).
Anaplastic histology
There was no signiﬁcant difference in OS between
FNRT and photon RT for patients with ATC (Fig 5), with
median OS of 7 and 3 months, respectively (P Z .20).
The Kaplan-Meier estimated OS at 1 year was 29% and
21%, respectively. In addition, we examined the effect ofFigure 2 Survival outcomes based on treatment modality.
Kaplan-Meier curves demonstrating OS with 95% conﬁdence
interval. Vertical lines designate censored events. OS, overall
survival; RT, radiation therapy.
Figure 3 Survival outcomes for well-differentiated histologies
based on treatment modality. Kaplan-Meier curves demon-
strating OS with 95% conﬁdence interval. Vertical lines desig-
nate censored events. OS, overall survival; RT, radiation
therapy.
Figure 5 Survival outcomes for anaplastic thyroid cancer
based on treatment modality. Kaplan-Meier curves demon-
strating OS with 95% conﬁdence interval. Vertical lines desig-
nate censored events. OS, overall survival; RT, radiation
therapy.
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was no signiﬁcant difference in OS overall, with median
OS of 3 months with DM and 6 months without (PZ .45,
data not shown). To attempt to examine any beneﬁt for
FNRT on local control, we examined the OS of the ATC
patients without DM with respect to treatment type
(Fig 6). Here, there was a trend toward improved OS with
FNRT (median OS 7 vs 4 months); however, this did not
reach signiﬁcance (P Z .15). Of note, the 2 patients to
survive for more than 2 years were in the FNRT group
(41 and 47 months).Discussion
Thyroid cancer is a rare diagnosis, with each primary
histology mandating tailored treatment approaches
resulting in varying outcomes. For well differentiated andFigure 4 Survival outcomes for medullary thyroid cancer
based on treatment modality. Kaplan-Meier curves demon-
strating OS with 95% conﬁdence interval. Vertical lines desig-
nate censored events. OS, overall survival; RT, radiation
therapy.MTC, EBRT is recommended in advanced cases in which
local recurrence is likely. For ATC, it is used as part of
trimodality therapy. At our institution, patients with
advanced thyroid cancer have been treated with both
FNRT and photon RT. Here we report our institutional
experience, comparing these modalities for the ﬁrst time.
Our current series presents outcomes from a very high-
risk patient cohort treated over the past 30 years. Nearly
all patients (97%) had stage IV disease according to the
2010 AJCC staging criteria, and all had evidence of either
gross residual disease, nodal metastases with or without
extracapsular extension, positive margins, or recurrence.
Twenty-four patients (39%) had ATC. Despite these
adverse features, estimated OS at 1 year for the cohort
was 90%, 78%, and 23% for well differentiated, MTC,
and ATC, respectively. These compare favorably with
similar data for OS at 1 year for all stage IV patients of
77.5 and 65.4 for PTC and FTC, respectively; 55% forFigure 6 Survival outcomes for patients with anaplastic thy-
roid cancer and no evidence of distant metastasis. Kaplan-Meier
curves demonstrating OS with 95% conﬁdence interval. Vertical
lines designate censored events. OS, overall survival; RT, radi-
ation therapy.
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patients with advancing age, ATC, and concurrent
chemotherapy had worse OS. The ﬁrst 2 factors would be
expected to lead to worse survival because age is an
independent prognostic factor in AJCC staging and ATC
has a dismal overall prognosis. In this case, the presence
of chemotherapy is most likely indicative of more
advanced disease warranting aggressive therapy in the
ATC subset. For the overall cohort, there was an increase
in median OS from 16 to 26 months when comparing
photon RT and FNRT, respectively. This ﬁnding was not
statistically signiﬁcant P Z .49; however, it is worth
noting that there is a separation of the survival curves
after the ﬁrst year, potentially indicating an improvement
in durable local control with FNRT.
The mainstay of treatment of well-differentiated
thyroid cancer is surgical resection with continued
debate surrounding the need for total (or near-total) thy-
roidectomy versus unilateral lobectomy.32,33 In a study of
more than 50,000 patients with PTC, total thyroidectomy
was shown on multivariate analysis to predict improved
local recurrence and survival rates for tumors >1 cm, and
therefore current American Thyroid Association recom-
mendations include total thyroidectomy in most
cases.10,34 RAI ablation routinely follows surgery for
patients with extrathyroidal extension or tumors >4 cm. It
is also often indicated for tumors >1 cm with known
lymph node metastases or other high-risk factors.10 RAI
administration has been shown to improve locoregional
relapse-free rate in these patients, but not in those with
lower risk factors.35 EBRT has typically been reserved for
patients presenting with extensive local disease, particu-
larly those with positive margins, gross residual disease,
or nodal metastases. In 1 retrospective study from Essen
(Germany), the addition of EBRT to surgery, RAI, and
thyroid-stimulating hormone suppression improved time
to locoregional recurrence (PZ .004) and time to distant
failure (P Z .0003).36 The patients in that study were all
>40 years old with pT4 disease, and the effect was most
signiﬁcant in those with nodal disease. In addition, a
study from Hong Kong demonstrated a survival beneﬁt
for patients with gross residual disease after surgery, with
OS at 5 years 67% versus 38% without RT (PZ .001).37
Although there are some conﬂicting reports in the litera-
ture, the majority of studies show an improvement in
locoregional control and/or survival with the addition of
EBRT.8,38 In spite of this improvement, approximately
15% to 25% of patients will experience local recurrence.8
A recent retrospective study from Manchester (UK)
investigated patterns of recurrence after EBRT. The
authors showed that 12 of 49 (24%) treated patients had
local recurrence, with 4 in the thyroid bed and 8 in the
regional lymph nodes.14 Given the inadequate local con-
trol, even after EBRT, we investigated whether the use of
FNRT in the well-differentiated patient subgroup could be
beneﬁcial. However, for the patients treated in our cohort,FNRT appears to confer a signiﬁcant survival detriment
when compared with photon RT, with OS at 1 year 57%
versus 86% (PZ .04), respectively. For any retrospective
study, there are inherent biases in patient selection that
could account for the difference seen; however, the
patients appear to be relatively well distributed. The
explanation for this is unclear. FNRT doses were selected
based on isoeffective normal tissue tolerances rather than
a known RBE for thyroid malignancies; however, the
RBE for neutrons has been shown to be up to 8 for certain
slow-growing malignancies such as adenoid cystic carci-
nomas.29 Because well-differentiated thyroid cancers are
also relatively slow growing, tumor underdosing versus
photon RT is unlikely, though possible. It is also possible
that an increase in toxicity with FNRT could be respon-
sible for this difference, particularly because patients at
the beginning of our study were treated with a higher dose
(>2000 NcGy) versus 1840 NcGy in the modern era.
Doses of >2000 NcGy have been shown to cause a 40%
incidence of grade 3 to 5 late toxicities in head and neck
cancer patients.31
In contrast to thyroid cancers arising from follicular
cells, there is little role for RAI in MTC because paraf-
ollicular cells do not concentrate iodine. The standard of
care therefore is total thyroidectomy (because of the high
rate of bilateral disease).11 Again, as with well-
differentiated disease, EBRT is reserved for patients
with locally advanced disease with a high risk of local
recurrence. Historical data suggest a limited role for
EBRT in the treatment of MTC, with 1 retrospective
French study demonstrating a 30% in-ﬁeld recurrence rate
in the treatment of 59 patients in the adjuvant setting.15
This was reinforced by a recent Surveillance Epidemi-
ology and End Results (SEER) study that showed no
survival beneﬁt in patients with involved nodes.39 As with
well-differentiated disease, however, the intent in treating
with EBRT is to improve local control, and several small
retrospective studies have shown it to be effective in this
regard.40,41 For example, a recent study from M D
Anderson examined 34 patients with a high risk of local
recurrence. There was no control arm in the study; how-
ever, an 87% local relapse-free rate at 5 years compares
favorably with historical data.42 The data in our study
highlight the uncertain beneﬁt of EBRT in MTC, with
only 10 patients treated over the course of 30 years.
Although there is a large difference in median OS, with
211 months for FNRT and 54 months for photon RT, this
ﬁnding is not signiﬁcant (PZ .19), as might be expected
with such small patient numbers. That all long-term
survivors are in the FNRT is interesting however and
lends itself to further study. As with all thyroid cancers
however, enrolling patients in prospective studies is
complicated by the low number of patients eligible for
EBRT, particularly in the case of MTC.
Unlike well-differentiated and MTC, ATC has a uni-
formly grim prognosis, with median OS of 5 months and
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SEER analysis that showed a median OS of 4 months and
a 19.3% 1 year OS.16 Patients typically present with a
rapidly growing neck mass that can be rapidly fatal
without intervention because airway compromise; there-
fore, current American Thyroid Association recommen-
dations include a clear discussion of goals of care and
rapid multidisciplinary evaluation before proceeding.12
Surgical excision is routinely the standard of care, either
in an attempt to obtain negative margins or to debulk
gross disease in the palliative setting. Given the rapid
repopulation of ATC, many groups have investigated
aggressive adjuvant therapy, with EBRT with or without
chemotherapy.8 The SEER study mentioned previously is
1 of the largest population-based studies, in which 120 of
197 patients received EBRT, with improved OS in the
subset with invasion into surrounding structures
(PZ .05). There was no beneﬁt if the cancer was capsule
conﬁned. In addition, a retrospective study from Princess
Margaret Hospital showed an OS beneﬁt for radical sur-
gery and deﬁnitive RT compared with palliative RT (11.1
vs 3.2 months, P < .0001)43; however, this and many
other studies are potentially compromised by selection
bias in the treatment groups, with healthier patients with
better prognostic factors receiving more aggressive care.
One recent prospective study performed at the Institut
Gustave-Roussy (France) examined an aggressive multi-
modality approach in 30 patients, with surgery followed
immediately by chemotherapy with cisplatin and doxo-
rubicin for 2 cycles. Patients then received hyper-
fractionated EBRT with 1.25 Gy twice a day to a dose of
40 Gy (patients treated later received boosts to 50-55 Gy).
This study produced quite remarkable results, with 1- and
3-year OS of 43% and 27%, respectively.44 Median OS
was 10 months in this cohort, indicating a potential for
improved outcomes with this technique; however, it was
associated with signiﬁcant esophagitis and neutropenia. In
contrast, a recent retrospective study from M D Anderson
examined the outcomes for ATC in the modern era, again
using surgery with concurrent chemotherapy and RT. In
their study of 53 patients (with 31 treated with deﬁnitive
intent), 81% received chemotherapy. Estimated OS at 1
year was 29% for patients treated deﬁnitively, more in
line with historical data. Of note, patients without DM
receiving >50 Gy had better OS.28 As can be seen, in
spite of recent advances in chemotherapy and treatment
techniques, OS in ATC remains poor. Because ATC is
considered radioresistant to traditional photon RT, we
hypothesized that FNRT might overcome this radio-
resistance and that the shorter treatment time might reduce
the effect of rapid repopulation and improve OS. Overall,
ATC patients in our study had a median OS of 4 months,
in line with those published in the literature. The use of
FNRT improved this to 7 months, with a 1-year estimated
OS of 29%; however, this increase was not statistically
signiﬁcant (PZ .20). When removing patients with DM,median OS remained 7 months versus 4 months for
photon RT (PZ .15). Therefore, in this cohort of 24 ATC
patients, there does not appear to be a clear beneﬁt for
FNRT over photon RT. It is possible that inherent biases
in the treatment groups may preclude a difference from
being seen. Also, the comparison may be underpowered
and any effect on local control may be rendered irrelevant
as patients typically die of DM (even with no evidence of
DM at presentation). Interestingly, the 2 patients with
longest survival in the ATC group (44 and 47 months)
received FNRT. A number of patients in the photon RT
group (71%) received concurrent chemotherapy (most
often low-dose doxorubicin). This was a negative prog-
nostic factor for survival in both the uni- and multivariate
analysis, indicating that concurrent chemotherapy should
be used with caution; however, this could again represent
bias in patient selection.
We acknowledge potential limitations of our study.
Upon review of the charts, there were insufﬁcient data to
report locoregional control or toxicity in our patient
cohort. These data are important and should be prospec-
tively collected in future studies. One of the strengths of
our study is the high number of true events collected for
data analysis, with very few censored events or patients
lost to follow-up. In addition, selection biases, physician
preference, and nonrandomization to treatment arms are
always problematic and difﬁcult to reconcile in retro-
spective reviews. The rarity of thyroid cancer and the
excellent outcomes for well-differentiated and low-grade
disease are reﬂected in the small number of patients
treated at our institution over a 30-year period and explain
the heterogeneity in histology, extent of disease, and
treatment technique. These issues have led to failed at-
tempts to perform prospective, randomized studies in
thyroid cancer, with a recent European multicenter study
of differentiated thyroid carcinoma unable to accrue suf-
ﬁcient patients secondary to clinician’s beliefs and referral
patterns.45 Given the difﬁculties with accruing patients to
randomized studies, we are limited to carefully performed
retrospective studies such as ours, reporting for the ﬁrst
time a comparison of FNRT and photon RT in patients
with thyroid cancer. Here we show overall treatment
results that compare favorably with those published in the
literature. Accepting the implications of a nonrandomized
study, we show that FNRT may be detrimental in the
treatment of well-differentiated histologies. In addition,
we show that there may be a small (but not signiﬁcant)
beneﬁt for FNRT in the treatment of MTC and ATC and
recommend further research in this area. In the case of
ATC, there has been much interest recently in the use of
tyrosine kinase inhibitors, such as sorafenib,46 imatinib,47
and axitinib,48 and BRAF inhibitors,49 which have all
demonstrated activity in ATC. It may be beneﬁcial to
combine these “targeted therapies” with aggressive RT to
improve both local and distant control, and a trial with
FNRT may make sense in this setting.
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In this retrospective review of a single-institution
experience treating locally advanced thyroid cancer,
FNRT does not confer a survival beneﬁt in comparison
with traditional photon techniques. Indeed, there is an
apparent detriment in OS with FNRT for well-
differentiated histologies. The trend toward improved
OS with medullary and anaplastic histologies warrants
further investigation.References
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